All News

Found 136 articles

• Aptinyx Highlights Key Goals and Anticipated Development Milestones for 2022

  1/6/2022

  Aptinyx Inc. today provided a corporate update and highlighted development milestones anticipated in 2022.

• 

  Incoming CEO Andy Kidd Prepares to Take Aptinyx to the Next Level

  1/4/2022

  Right now, Kidd’s focus is on ensuring the company is ready for late-stage development and commercialization activities.

• BD Announces Board of Directors for embecta, the Planned Spinoff of its Diabetes Care Business

  12/21/2021

  BD announced that Embecta Corp., the independent, publicly-traded company that will hold BD's Diabetes Care business upon the planned completion of the previously announced spinoff, will be governed by a nine-person board of directors.

• 

  Clinical Catch-Up: December 11-17

  12/20/2021

  It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look.

• Aptinyx to Host Virtual Portfolio Review Event on February 9th, 2022

  12/20/2021

  Aptinyx to Host Virtual Portfolio Review Event on February 9th, 2022.

• Aptinyx Initiates Phase 2b Study of NYX-783 in Patients with Post-Traumatic Stress Disorder

  12/16/2021

  Aptinyx Inc. today announced the initiation of a Phase 2b study evaluating 50 mg QD of NYX-783 in 300 patients with post-traumatic stress disorder (PTSD).

• Aptinyx to Present at the 40th Annual J.P. Morgan Healthcare Conference

  12/13/2021

  Aptinyx Inc. today announced that Andy Kidd, M.D., president & chief executive officer, will present at the 40th Annual J.P. Morgan Healthcare Conference.

• Aptinyx to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference

  11/18/2021

  Aptinyx to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference.

• Aptinyx Reports Third Quarter 2021 Financial Results and Recent Highlights

  11/9/2021

  Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, reported financial results for the third quarter of 2021 and provided key business updates across the company’s clinical-stage pipeline of novel NMDA receptor modulators.

• Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy

  10/27/2021

  Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, announced the completion of enrollment in the company’s ongoing Phase 2b study of NYX-2925 for the treatment of painful diabetic peripheral neuropathy.

• Aptinyx to Report Third Quarter 2021 Financial Results on Tuesday, November 9, 2021

  10/25/2021

  Aptinyx Inc. today announced that the company will host a conference call and live webcast on Tuesday, November 9, 2021 at 5:00 p.m. ET to report third quarter 2021 financial results and discuss recent business highlights.

• 

  BioSpace Movers & Shakers, Oct. 22

  10/22/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Aptinyx Appoints Gilmore O’Neill, M.B., M.M.Sc., to Board of Directors

  10/20/2021

  Aptinyx Inc. today announced the appointment of Gilmore O’Neill, M.B., M.M.Sc., to the company’s board of directors.

• Rosalind Franklin University Collaborates with Aptinyx to Research New Therapeutics for Brain Diseases

  9/22/2021

  Rosalind Franklin University of Medicine and Science is announcing a research collaboration with Aptinyx, a clinical-stage biopharmaceutical company, to support the development of new therapeutics for brain and central nervous system disorders.

• Aptinyx to Participate in 2021 Cantor Virtual Global Healthcare Conference

  9/20/2021

  Aptinyx Inc. today announced that Norbert Riedel, Ph.D., chief executive officer, will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on September 30, 2021 at 10:00 a.m. ET.

• Aptinyx Secures $50 Million Growth Capital Credit Facility from K2 HealthVentures

  9/16/2021

  Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, announced that it has entered into a $50 million loan facility and security agreement with K2 HealthVentures.

• Aptinyx to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

  8/31/2021

  Aptinyx to Participate in H.C. Wainwright 23 rd Annual Global Investment Conference

• Aptinyx Reports Second Quarter 2021 Financial Results and Business Highlights

  8/10/2021

  Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today reported financial results for the second quarter of 2021 and provided key business updates.

• Aptinyx to Participate in 2021 Wedbush PacGrow Healthcare Virtual Conference

  8/3/2021

  Aptinyx Inc. today announced that Norbert Riedel, Ph.D., chief executive officer, will participate in the “Brains of the Operation - Novel Approaches in Neuro” panel discussion at the Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 10 at 12:00 p.m. ET.

• Aptinyx to Report Second Quarter 2021 Financial Results on Tuesday, August 10, 2021

  7/26/2021

  Aptinyx Inc. today announced that the company will host a conference call and live webcast on Tuesday, August 10, 2021 at 5:00 p.m. ET to report second quarter 2021 financial results and discuss recent business highlights.